CAI named as an official Kneat Platform Partner see more
CAI, a global consulting company that provides technical, operational consulting, and project management services to life sciences, data centers, and industrial process manufacturing industries, today confirmed its status as an official Kneat Platform Partner with the launch of its own validated Kneat Gx software instance following the initial development of a strategic partnership with Kneat Solutions in early 2022.
The Kneat Gx instance, a 21 CFR Part 11 and Annex 11 electronic records and signatures compliant SaaS validation solution, enables CAI to host work product on behalf of its clients, including reviews, approvals, and execution of protocols.
The CAI instance of Kneat Gx will provide a mechanism for Knowledge Management that is married directly to work product, by enabling tools and templates to be stored and managed in the same platform and format, where they can and should be used.
“Our Kneat Gx environment gives us the ability to serve our clients more efficiently, using industry best in class standardized off-the-shelf content while removing the geographic obstacles to collaboration within our global network of industry professionals,” states Mike Martin, CEO of CAI. He continues, “I am excited for what the future holds!”
“CAI continues to demonstrate their commitment to enhancing their client experience and results through the adoption of digital validation and through their partnership with Kneat,” commented Rick Mineo, Director of Strategic Partnerships at Kneat. “We are very pleased to partner with CAI, and we look forward to continuing to scale our solutions”
Since CAI’s founding in 1996, we have delivered nearly a billion dollars in services for hundreds of clients across thousands of projects globally. With offices in the US, Canada, Australia, Netherlands, Korea, Switzerland, India, Ireland, Italy, China, Singapore, United Kingdom, and Malaysia, we have built an international team of over 850 professionals providing local support from a global company. Our engineering, technical, and consulting services deliver mission critical facilities with a high level of performance and reliability. When operational readiness is critical, CAI delivers to a higher standard. https://cagents.com/
Kneat, a Canadian company with operational headquarters in Limerick, Ireland, develops and markets the next generation Kneat Gx SaaS platform. Multiple business work processes can be configured on the platform from equipment to computer system validation, through to quality document management. Kneat’s software allows users to author, review, approve, execute testing online, manage any exceptions, and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes globally. Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard. For more information visit www.kneat.com
Tiger scientists strut their stuff in ACC contest see more
A team of five women bioengineering students from Clemson University has won second place in the Atlantic Coast Conference InVenture Prize competition, in which teams of undergraduates representing each ACC university pitched their inventions or businesses before a live audience and a panel of judges.
The team collaborated with bioengineering design mentors and neurosurgeons at Prisma Health to invent a device, named the CatheSure, that detects hydrocephalus shunt malfunctions in children.
Hydrocephalus is fluid buildup in the cavities of the brain. The excess fluid increases the size of the ventricles and puts pressure on the brain. More than one million Americans suffer from the condition. The most common treatment is the surgical insertion of a drainage system, or shunt. Unfortunately, these shunts have a 70 percent failure rate, with 40 percent failing in the first year — and the symptoms of a shunt failure are often vague, usually similar to the common flu. Currently, the only way for doctors to diagnose a shunt failure is with invasive and expensive brain surgery.
The CatheSure is a pressure sensor that wirelessly detects a shunt malfunction in hydrocephalus patients in under five minutes to non-invasively determine if there is a shunt blockage or malfunction. Use of the device will streamline the diagnostic process and prevent unnecessary exploratory brain surgeries, prolonged hospital stays and repeated radiation exposure.
John DesJardins, the faculty director for entrepreneurship, and director of the Bioengineering Senior Design Program in the College of Engineering, Computing and Applied Sciences, said he was impressed by the work ethic and professionalism of the team.
“They’ve been under the gun for three weeks to get all their materials together, and then they had to get on stage live on PBS Saturday night and pitch it,” said DesJardins, who is also the Hambright Distinguished Professor in Engineering Leadership. “They were in with some pretty high-caliber talent from across the ACC, but they were totally prepared and really represented Clemson University well.”
The CatheSure team started this journey by winning the CECAS Spark challenge earlier this year, which led to them competing for the InVenture Prize. DesJardins said Clemson teams have participated four out of the five years the InVenture Prize competition has been held, but this is the first time one of them has placed.
“They’re on a roll!” said DesJardins.
Team member Allison Reichart said the process has deepened her passion for bioengineering:
“Winning second place at the ACC InVenture Prize Competition was a massive step in two directions. One, in helping hydrocephalus patients with ventriculoperitoneal shunts and two, breaking down barriers for women in a male-dominated field. I couldn’t be more honored or prouder to represent both and can’t wait to continue taking strides down these paths!”
Fellow team member Sarah Stevens said she is confident that CatheSure will make a positive impact in the lives of people affected by hydrocephalus.
“Throughout designing the CatheSure, our team has seen time and time again how bioengineering devices can make a truly positive impact on the lives of patients and family members affected by the problem we are solving.”
DesJardins said the next steps will be using the pathways at Clemson to get the CatheSure tested and patented, with the aim of getting it to market in three or four years.
The Clemson team tied for second place with Duke University and will split the $10,000 prize. The team members (all senior bioengineering majors) were:
- Kathleen Fallon
- Allison Reichart
- Jordan Suzanna Cole
- Sarah Anne Stevens
- Karly Faith Ripple
A South Carolina scientist works to solve a major health problem see more
Pediatric patients suffering from heart issues are treated with the existing adult surgical solutions, requiring repeated surgeries as the child grows. To understand the problems with current technologies, bioengineer Naren Vyavahare consults with clinicians and applies this knowledge to innovative, adjusted strategies. He develops new solutions in the lab and works with other experts and private sector companies to bring them to the marketplace. The inspiring impact of his commitment: a groundbreaking discovery that reduces surgical risk, patient and family trauma, and financial costs for pediatric patients that will last centuries.
In this episode, Naren Vyavahare joins our hosts Joseph Nother and Laura Corder to talk about the roles passion, teamwork, and plenty of research play in developing life-changing solutions for congenital heart disease. Listen as Naren Vyavahare talks about understanding “the why,” consulting with clinicians, and building a team of experts in business, cardiology, and research to discover the solution. Listen to the full podcast now.
Long-standing partnership between Clemson University and MUSC paying off see more
South Carolina is strengthening its position as a hub for high-impact biomedical research with a new multi-million-dollar project that undergirds the long-standing partnership between Clemson University and the Medical University of South Carolina (MUSC) and loops in crucial support from the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health (NIH).
Researchers will study temporomandibular joint (TMJ) function, how the TMJ functions in different craniofacial developmental disorders that seem to put the joint at risk for degeneration and how the joint responds to surgical correction of these disorders, researchers said.
The TMJ makes it possible to move the lower jaw to eat and talk. Understanding the stresses on the TMJ before temporomandibular joint disease (TMD) occurs will unlock the mechanisms that put certain individuals at risk for TMD.
The focus of the research aligns with the recommendations made by an ad hoc committee on temporomandibular disorders that was formed under the auspices of the National Academies of Sciences, Engineering, and Medicine’s Health and Medicine Division.
Four of the researchers involved in the new project are connected to the Clemson-MUSC Bioengineering Program. As part of the program, Clemson bioengineering faculty and students are based at MUSC’s Charleston campus where they collaborate closely with MUSC researchers and clinicians.
The new project, funded by a $3.18-million U01 grant from NIDCR, has two principal investigators. Hai Yao, serves as the Ernest R. Norville Endowed Chair and professor of bioengineering at Clemson, professor of oral health sciences at MUSC, the associate department chair for the Clemson-MUSC Bioengineering Program and a member of the national temporomandibular disorder ad hoc committee. Janice Lee is the clinical director of the NIDCR and chief of the Craniofacial Anomalies and Regeneration Section within the NIH intramural research program.
Yao said the project is possible only because of the synergy and complementary strengths of Clemson, MUSC and NIDCR.
“Clemson and MUSC work together so seamlessly it’s as if we are one university, and we both collaborate closely with NIDCR,” he said. “This project is the latest example of how these strategic partnerships are making South Carolina a hub of biomedical research that is recognized globally. Through these partnerships, we are well positioned to address urgent healthcare needs identified by the NIDCR and the National Academy of Medicine.”
Lee said the researchers are uniquely positioned for success.
“The U01 is an extremely competitive grant that requires intra- and extra- mural collaboration utilizing the world-renown resources at the NIH Clinical Center,” Lee said. “It is extra special as this is a first for NIDCR intramural as well. Temporomandibular joint disorders are debilitating conditions, and I am thrilled to be working with Hai Yao and his team to truly move the research forward. His team brings outstanding bioengineering technology to examine craniofacial musculoskeletal function to the Clinical Center; our discoveries will be translated and, ideally, will initiate first-in-human therapies for TMD at the NIH.”
Lee continued: “NIDCR is committed to working with world-class partners such as Clemson and MUSC to advance translational research into temporomandibular disorders. This project will help improve understanding of these disorders, thereby improving outcomes for patients.”
This is particularly important to Lee as she is the oral and maxillofacial surgeon who will be providing the surgical treatments and is acutely aware of the impact that surgery can have on TMD, she said.
Özlem Yilmaz, chair of the Department of Oral Health Sciences at MUSC, said the new project presents an important venue to help patients debilitated with TMJ disorders and underpins South Carolina’s leading position in temporomandibular disorders research.
“New measurement tools and computational models will be tested on patients at the NIH Dental Clinic,” Yilmaz said. “These novel technologies, stemming from more than a decade of teamwork bringing together bioengineers, oral surgeons, and oral biologists at MUSC and Clemson, will push the boundary of the current temporomandibular disorders research.”
Sarandeep Huja, dean of the College of Dental Medicine at MUSC, said the new project further solidifies MUSC’s partnership with Clemson and NIDCR.
“This partnership will help us innovate the future of oral health and wellness,” Huja said. “We will not only be advancing knowledge of temporomandibular disorders but also expanding knowledge for the next generation of oral health providers and researchers. As a practicing clinician and orthodontist, I frequently encounter patients with temporomandibular disorders, in the very type of patients that will be recruited in this study. It is critical we find evidence based treatments for these patients.”
The vice presidents of research at Clemson and MUSC are crucial to the institutions’ partnership, Yao said. Tanju Karanfil is vice president of research at Clemson, and Lori L. McMahon is vice president for research at MUSC.
“We look forward to solidifying the strong foundation that Clemson and MUSC have built,” Karanfil and McMahon said in a joint statement. “These large, high-impact projects are advancing knowledge and creating a new generation of talent, while strengthening the state’s national and international reputation for biomedical research and education.”
Researchers are calling their project “Assessment of Temporomandibular Joint Morphology, Mechanics, and Mechanobiology in Class II and III Target and Surgical Phenotypes.”
Part of what makes the project unique is the collaboration that maximizes the expertise of the investigators.
“Dr. Lee and her craniofacial team at NIDCR will recruit the large number of patients that will be required for the research, characterize the patients, and support their travel and treatment costs,” Yao said.
Clemson and MUSC will perform analysis of temporomandibular joint biomechanics and mechanobiology and put that information into context to better understand patients’ health status and the potential for future problems
Martine LaBerge, chair of Department of Bioengineering at Clemson, said the U01 grant that funds the new project is the first of its kind at Clemson.
“This grant is a testament to the strength of the biomedical research enterprise that Clemson and MUSC are building in partnership with federal collaborators, especially the National Institutes of Health,” she said. “Dr. Yao’s leadership has been crucial to the partnership’s success, and it remains in good hands with him at the helm.”
The project is the latest major NIH grant led by Yao. He is also principal investigator on South Carolina Translational Research Improving Musculoskeletal Health (SC TRIMH), a Center for Biomedical Research Excellence that was founded with an $11-million NIH grant in 2018. Researchers associated with the center have accounted for $8 million in NIDCR awards over the past year.
Anand Gramopadhye, dean of the College of Engineering, Computing and Applied Sciences, said the success underscores the high quality of research that has come out of interdisciplinary partnerships such as the Clemson-MUSC Bioengineering Program.
“Working together in collaboration with federal partners is elevating South Carolina’s position as a place for top-tier biomedical research and predoctoral and postdoctoral education,” he said. “Dr. Yao and his team have built a high-impact program and are continuing to climb. I offer them my whole-hearted congratulations.”
Workforce development in life sciences in SC takes another step forward see more
Clemson University has introduced a new Master of Science in Medical Device Reprocessing program open to graduates holding a bachelor’s degree in STEM disciplines.
Designed by industry experts, the yearlong, 30 credit hour program emphasizes optimizing and validating biomedical technologies to support safe reuse of medical devices and healthcare products. Integrating fundamental principles of bioengineering, industrial engineering, medical device design and quality science, the curriculum is eleven graduate-level courses and an immersion/training experience in research or industry. Students enter the asynchronously offered online program in the fall semester and graduate the following summer after an industry internship or mentored research on a medical device reprocessing team.
Medical device “reprocessing” involves the cleaning, disinfection, and sterilization of medical devices after each use. Reprocessing is an essential practice in healthcare delivery and plays a key role in the more than 100 million surgical procedures in the U.S. each year. The Master of Science degree program in Medical Device Reprocessing curriculum provides skills to innovate solutions that address global challenges affecting medical device safety and healthcare sustainability.
The degree program is based on a core curriculum applying knowledge of fundamental principles of bioengineering and industrial engineering; medical device design; and quality science in an industry immersion/training program along with relevant science and engineering applications.
The goal is to prepare globally engaged students to be innovative industry leaders in sustainable biomedical technology through training in modern reprocessing and sterilization technologies, quality science, and human factors in healthcare Graduates will be able to integrate and apply knowledge of:
- medical device design principles to enable reprocessing
- human factors engineering
- the science of sterilization and its impact on materials
- microbiology and the role of process validation and controls
- systems engineering
- supply chain management and
- Six Sigma quality control and regulatory science.
For additional information, candidates and employers are invited to contact Melinda Harman, Ph.D., Program Director & Associate Professor of Bioengineering by email at firstname.lastname@example.org or by calling 864-656-4140.
Accolades pour in for celebrated Clemson educator and leader see more
Clemson University's Dr. Martine LaBerge is the recipient of InnoVision’s 2021 Dr. Charles Townes Individual Achievement Award in recognition of her impressive career leading Clemson University’s Bioengineering department and its many initiatives and collaborations around South Carolina. Dr. LaBerge was honored Tuesday, November 9th when Innovision celebrated her achievements, contributions and leadership.
View the Award Presentation video here.
Congratulations to Martine from the entire SC life sciences community and SCBIO!
Clemson start-up getting noticed see more
When innovation and expertise meet practicality, the result is not quite magic, but it sure is close.
This is the strength behind Aravis BioTech, a startup headed in part by Jeffrey Anker of the College of Science and John DesJardins of the College of Engineering, Computing and Applied Sciences, as well as Dr. Caleb Behrend, an orthopedic surgeon in Arizona specializing in the spine. The team is developing screws used in orthopedic surgery that employ easy-to-use sensors to determine the status of fracture healing. This, in turn, helps physicians know when patients can safely apply weight to their healing fracture.
Aravis BioTech is one of three finalists for the InnoVision Technology Development Award. InnoVision is a non-profit organization that fosters the growth of South Carolina’s innovation economy and recognizes leadership, innovation and technological excellence.
“My background is in analytical chemistry – which means I make sensors,” said Anker, a professor in the Department of Chemistry.
Anker and DesJardins, a professor in the Department of Bioengineering, met on a bus at a student NASA project at the Marshall Space Flight Center in 2010. The pair decided to bring their work together to develop a medical implant that would change color as a fracture healed. Through a grant from SC BioCRAFT (Bioengineering Center for Regeneration and Formation of Tissues) and an NIH grant, they developed screws that changed color based on how tight they were.
But Dr. Behrend, a spine surgeon and longtime friend and collaborator of Anker’s, said that such a sensor would be more practical if surgeons could see it on an X-ray.
“Most Americans will break a couple of bones, on average, in their lifetime,” Anker said. “If it’s a bad break and you can’t just put a cast on it, they need to put in hardware. That’s where those screws come in.”
An X-ray doesn’t show how well a bone is healing. Between the break and full healing, there is an intermediate phase where the repaired fracture can and should bear weight – the question is how much.
“Maybe it can take your weight for a bit, but it will eventually fatigue and fail,” Anker said. “Similar to a paper clip, I can bend it a lot, but if I go back and forth, back and forth, eventually it will fail. The same thing happens with these implants. That’s a huge problem.”
Consider a hip fracture. Anker said one in 10 Americans will break hips. Rather than replacing the hip, the most common repair is to secure the ball back to the femur with a simple screw.
“People are encouraged to bear weight immediately, but if it’s not healing, the screw will probably eventually cut out of the bone or there will be other mechanical failures,” Anker said. “That happens rarely, but when it happens, it’s devastating.”
The screw is positioned into the bone repair with a wire guided through its hollow core. Aravis BioTech’s implanted device enhances the screw.
“We add a straight piece to the bottom of the hollow screw so that when it bends, this straight piece moves relative to the screw casing,” Anker said. “We make that straight piece out of a material that is dark on X-rays. You can see how much the screw is bending, quantify how much load is on it and be able to track the patient’s progress.”
The implant can help surgeons determine whether the device has been tightened sufficiently during surgery. And because load can lead to postoperative failure, it can help determine whether the patient is at an optimum activity level or if activity needs to be reduced until further healing takes place. Once the bone has healed, the hardware typically stays in and becomes superfluous.
A technology translation grant from the National Science Foundation’s Innovation Corps (ICORPS) program to Clemson University allowed the Aravis team to interview a variety of stakeholders, including physicians, patients, physical therapists, insurance executives and hospital administrators to determine if the team is making a device that best meets the needs of patients. A South Carolina Research Authority (SCRA) Acceleration Grant helped fund prototypes.
The team is expanding the idea to plates and other devices, as well as to sensors that can track infection based on chemical changes.
In addition to Aravis BioTech’s honor as an InnoVision Technology Development Award finalist, all four finalists for InnoVision’s COVID-19 Response – Technology Research Award are from Clemson University, including the COVID Microbead Screening Project, a team mentored by Anker, which also won the Clemson COVID Challenge, a summer virtual research and design opportunity. The team investigated a quick COVID-19 test that uses minimal, easily accessed equipment.
Clemson targets fix for mask shortage see more
(Courtesy, Paul Alongi, Clemson College of Engineering, Computing and Applied Sciences)
Melinda Harman of Clemson University is volunteering her time to explore how hospitals could wash and sanitize medical masks without having to ship them elsewhere or buy an expensive piece of equipment.
A device that Harman designed to hold multiple N95 masks is central to her idea. It would help ensure the masks maintain their shape while being washed so that they continue to fit securely around the mouth and nose, said Harman, an associate professor of bioengineering and director of Clemson University’s Medical Device Recycling and Reprocessing program, or GreenMD.
The masks help prevent healthcare workers from inhaling the novel coronavirus that causes COVID-19 and have been in short supply since the pandemic began.
As part of her work, Harman said she has engaged three leading healthcare companies that offer expertise in detergents and decontamination. She is testing different kinds of detergents to find the best solution for cleaning mucus and proteins from the masks.
The detergents are commercially available and already used by hospitals to clean other types of medical equipment.
Harman said that her goal is “to validate a cleaning process that is compatible with existing capabilities and equipment commonly available at hospitals in South Carolina and worldwide.”
The challenge is “to avoid interfering with mask performance, while effectively cleaning the masks without degrading their filtering capacity,” she said.
Harman added, “Working with innovative industry partners is a considerable advantage, with everyone on the team willing to contribute a potential solution. They are providing reliable products that are already proven to meet routine reprocessing challenges in healthcare delivery.”
Harman said one of the advantages to her approach is that many hospitals already have the ability to clean medical equipment, even if they aren’t yet applying it to the masks. That means hospitals wouldn’t need to buy any capital equipment, she said.
Further, the masks would stay at the hospital, reducing travel time, the risk of spreading contamination outside of the hospital and the additional burden on an already-stressed logistics system, Harman said.
“The technology I’m working on is meant to be used broadly, compatible with existing reprocessing practices that are already in hospitals,” Harman said. “It’s intended for rapid deployment in health care settings, and it’s meant to be compatible with any sterilization system.”
Harman added, “Cleaning masks before sterilization enables more masks to be reused Right now, guidelines for sterilization require N95 masks to be inspected and discarded if they are ‘soiled.’ My idea is to reliably clean masks to remove both the visible and ‘invisible’ soils, making the entire reuse process safer.”
Martine LaBerge, chair of the Department of Bioengineering, said that Harman is well qualified to lead the work.
Harman has conducted extensive research into reuse and reprocessing of medical equipment. As director of GreenMD, she engages students in industry-driven research targeting healthcare needs in South Carolina and broader global health challenges. GreenMD is the nation’s only engineering-focused program for medical device design targeted for reprocessing and reuse.
“Dr. Harman has built a career on developing innovative ways to reprocess and reuse medical equipment that is normally disposable, which uniquely positions her to have a global impact,” LaBerge said. “I thank her for her service to South Carolina, the nation and the globe as we join together in the face of the unprecedented challenges posed by COVID-19.”
Harman said that if her idea works, used masks would be sent to central sterilization facilities within hospitals. The device she designed would hold the masks while they are cleaned. After cleaning, the masks would go through a separate sterilization process to get rid of any lingering microorganisms, including coronavirus.
The mask-holder that Harman designed could be 3D-printed, she said. However, she is focusing on more rapid manufacturing approaches using common acrylic materials. The technology could be readily adapted in hospitals from South Carolina to India, Harman said.
She recently disclosed the technology to the Clemson University Research Foundation, setting it on the path to commercialization and raising the potential for widespread use.
Harman said what’s been most interesting to her is that her previous work with resource-poor countries has come home to the United States, with disrupted supply chains and inadequate supplies at the point of need.
“That’s exactly the situation we’ve been working on with other countries,” Harman said. “For me that’s just been a startling change. It’s been amazing to see how many people have become interested in the topic of safe and sustainable reuse and how many unique solutions they come up with. I hope that creative energy continues, because it can solve a lot of global health problems.”
Multimillion-dollar grant to support heart health research at Clemson University see more
Clemson University bioengineers picked Valentine’s Day to announce $4.1 million in grants to support new heart health research.
Will Richardson and Naren Vyavahare are conducting research with the potential to affect millions of patients who suffer from many forms of cardiovascular disease and related illness, including heart failure, hypertension, chronic kidney disease and Type 2 diabetes, according to a university news release.
Richardson, an assistant professor of bioengineering, is creating computer models aimed at providing better treatment for cardiac fibrosis, a condition that contributes to heart failure. As many as 60% of patients die within five years of developing heart failure, which afflicts 6.5 million Americans, Richardson said in the news release.
No drugs have been approved to treat cardiac fibrosis specifically, and doctors are often left with trial-and-error experimentation when treating patients who have it, he said in the release.
Richardson said he hopes his research will lead to a day when measurements from a patient’s blood or tissue sample can be plugged into mathematical equations based on how molecules interact in the body. Overnight, patients would have personalized risk assessments and treatments plan, he said in the release.
Details about his research is available online.
Vyavahare, the Hunter Endowed Chair of Bioengineering, is working on what could be the first treatment to reverse vascular calcification, a condition that occurs when mineral deposits build up on blood vessel walls and stiffen them, according to the news release. It is most prevalent in aging patients and those with chronic kidney disease and Type 2 diabetes, Vyavahare said. Complications from vascular calcification can range from hypertension to death.
The nanoparticles that Vyavahare is developing are many times smaller than the width of a human hair and would deliver two medicines to calcified blood vessels. One medicine would remove the mineral deposits that cause blood vessels to become calcified, and another would return elasticity to the blood vessels.
More details about his work is online.
The Richardson and Vyavahare projects were both funded through the National Institutes of Health’s R01 program. Richardson is receiving $1.9 million, and Vyavahare is receiving $2.2 million, the news release said.
Anand Gramopadhye, dean of the College of Engineering, Computing and Applied Sciences, congratulated Richardson and Vyvahare on their grants.
Agneta Simionescu, an assistant professor of bioengineering, has also received $1.38 million through the R01 program. The Simionescu award was announced in November and is aimed at better understanding cardiovascular disease in patients with diabetes, the news release said.
Richardson and Simionescu were among the faculty members trained as part of SC BioCRAFT, a National Institutes of Health Center of Excellence. The center’s primary goal is to increase the number of South Carolina biomedical researchers who are supported by grants from the National Institutes of Health.
Vyavahare leads SC BioCRAFT, which stands for the South Carolina Bioengineering Center for Regeneration and Formation of Tissues.
Clemson University ranks fourth among America's 50 best value schools for biomedical engineering... see more
Clemson University came in fourth among the nation’s 50 best value schools for biomedical engineering, according to a new ranking from bestvalueschools.com.
The ranking included a variety of factors, including graduation rate, accreditation date, degree popularity, engineering popularity and net price.
Martine LaBerge, SCBIO Board Member and chair of the Department of Bioengineering at Clemson, said the ranking underscores that students are receiving a high-quality education that remains affordable.
“Best Value Schools has done an impeccable job of describing our program,” she said. “The ranking is a result of our faculty’s hard work and dedication to giving our students not only the best-in-class instruction and experience but also great value.”
The website advised students to “get ready to get hands-on at Clemson University.”
“Just about every day at Clemson includes some type of laboratory study, research project, or side-by-side work with faculty,” according to the site.
“Coursework doesn’t spare the details, either; the curriculum goes far beyond the basics to teach students about orthopedic implants, EKG simulations, medical treatment in developing countries, tissue engineering for human organs, and plenty of other topics that will immediately translate into the work environment.
“And students don’t have to wait until graduation to test out their skills. International partnerships enable budding engineers to conduct research in Singapore, work with mentors in Japan, or study bioethics in Spain.”
The department graduated 158 students last year, including 106 undergraduates, 37 master’s students and 15 doctoral students. It has 26 tenured or tenure-track faculty members conducting bioengineering research and clinically embedded education in partnership with the Greenville Health System and the Medical University of South Carolina.
Citing numbers from the U.S. Bureau of Labor Statistics, the website reported that demand for biomedical engineers will increase by nearly 25 percent by 2024, which it says is much faster than the average occupation. The average salary for specialists in the field is more than $85,000 a year, according to the site.
Clemson came in behind the Georgia Institute of Technology, Rice University, and the University of California-Irvine. The University of Utah rounded out the top five.
Anand Gramopadhye, dean of Clemson’s College of Engineering, Computing and Applied Sciences, congratulated the bioengineering department on the ranking.
“This is a well-deserved honor that underscores the high return on investment our students receive,” he said. “The college will continue to offer access to top faculty, world-class facilities and enriching experiences, while ensuring investment returns remain strong for our students and their families.”
To see the full list of rankings, go to: https://www.bestvalueschools.com/rankings/biomedical-engineering-degrees/.